David Winslow
Pulmonary Disease · Louisville, KYNPI 1356437511
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by ZOLL Respicardia, Inc. at 40.2% of the total. Reporting peaked in 2019 at $4,328 and has fallen 88.3% since, to $505 in 2022.
Across 173 payments — averaging $51.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$4K
- Harmony Biosciences LLC$2K
- GSK$953
- AstraZeneca$555
- Boehringer Ingelheim$469
- Jazz Pharmaceuticals Inc.$390
- plus $1K from 17 others
Across 279 payments — averaging $1512.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$304K
- Livanova USA, Inc.$62K
- Jazz Pharmaceuticals Inc.$50K
- Harmony Biosciences LLC$6K
What the payments were for
- Consulting fees$4,80054%
- Food & beverage$4,06245%
- Education$961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 2 | $3,600 |
| Harmony Biosciences LLC | 8 | $1,615 |
| GSK | 43 | $953 |
| AstraZeneca | 13 | $555 |
| Boehringer Ingelheim | 22 | $469 |
| Jazz Pharmaceuticals Inc. | 15 | $390 |
| Insmed, Inc. | 13 | $230 |
| Actelion Pharmaceuticals US, Inc. | 12 | $224 |
| Mylan Specialty L.p. | 9 | $167 |
| Teva Pharmaceuticals USA, Inc. | 2 | $132 |
| Genentech USA, Inc. | 9 | $124 |
| Sanofi | 6 | $107 |
| Pulmonx Corporation | 1 | $96 |
| CSL Behring | 3 | $64 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $40 |
| Electromed, Inc. | 3 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Fisher & Paykel Healthcare Inc | 1 | $19 |
| United Therapeutics Corporation | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$3,600
- Wakix$1,433
- FASENRA$325
- ANORO$235
- TRELEGY ELLIPTA$218
- CINQAIR$121
- SYMBICORT$107
- BREZTRI$102
- XYWAV$102
- SUNOSI$102
How this compares
$8,958 in reported general payments places this provider in the 70th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.